Please use this identifier to cite or link to this item: https://ir.swu.ac.th/jspui/handle/123456789/29396
Full metadata record
DC FieldValueLanguage
dc.contributor.authorHamontri S.
dc.contributor.authorTantitamit T.
dc.contributor.otherSrinakharinwirot University
dc.date.accessioned2023-11-15T02:08:32Z-
dc.date.available2023-11-15T02:08:32Z-
dc.date.issued2023
dc.identifier.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85158100635&doi=10.31557%2fAPJCP.2023.24.4.1401&partnerID=40&md5=fd6dcf90fb87faaffe34131b968dc9b3
dc.identifier.urihttps://ir.swu.ac.th/jspui/handle/123456789/29396-
dc.description.abstractObjective: To determine the survival outcomes and prognostic factors of the patients with recurrent platinumresistant and refractory epithelial ovarian cancer (EOC), tubal, and peritoneal cancer. Methods: Women with recurrent platinum-resistant and refractory EOC, tubal and peritoneal cancer who received treatment at the HRH Princess Maha Chakri Sirindhorn Medical Center (MSMC) between January 2010 and December 2019 were included. Demographic data, serum marker, surgical factors, pathological factors and response of treatment were reviewed. Kaplan-Meier was used to calculate survival outcome. Result: Forty patients were recruited in this study (platinum-resistant 24 patients and refractory 16 patients). The median survival times were 19 and 21 months in and platinum-resistant and platinumrefractory patients, respectively. There were no significant differences in overall survival according to age, comorbidity, tumor grading, primary treatment, and secondary surgery. However, histology of clear cell carcinoma may associate with increased risk of death. The median overall survival of patients with clear cell carcinoma, serous carcinoma, and others were 14.4, 22.9, and 32.2, respectively (p = 0.003). Conclusion: Almost 10 years, the survival rate of the patients in these group has not increased despite new treatments option. Novel strategies should be considered in National policy of the treatment for ovarian cancer in our country © This work is licensed under a Creative Commons Attribution-Non Commercial 4.0 International License
dc.publisherAsian Pacific Organization for Cancer Prevention
dc.subjectOvarian cancer
dc.subjectprognosis
dc.subjectrecurrence
dc.subjectsurvival
dc.titleOutcomes and Prognostic Factors of Patients with Platinum-Resistant or Refractory Epithelial Ovarian Cancer, Fallopian Tube Cancer and Peritoneal Cancer
dc.typeArticle
dc.rights.holderScopus
dc.identifier.bibliograpycitationAsian Pacific Journal of Cancer Prevention. Vol 24, No.4 (2023), p.1401-1405
dc.identifier.doi10.31557/APJCP.2023.24.4.1401
Appears in Collections:Scopus 2023

Files in This Item:
There are no files associated with this item.


Items in SWU repository are protected by copyright, with all rights reserved, unless otherwise indicated.